A vaccine against methamphetamine attenuates its behavioral effects in mice

Drug and Alcohol Dependence

Volumn 129, Issue 1-2, 2013, Pages 41-48

  Shen, Xiaoyun Y ^a   Kosten, Therese A ^b   Lopez, Angel Y ^a   Kinsey, Berma M ^a   Kosten, Thomas R ^b   Orson, Frank M ^a  

^a Immunology Allergy and Rheumatology   (United States)

^b BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

Conditioned place preference; Conjugate vaccine; Keyhole limpet hemocyanin; Locomotor activity; Monophosphoryl lipid A; Serum antibody titers

Indexed keywords

DRUGS USED IN THE TREATMENT OF ADDICTION; SUCCINYL METHAMPHETAMINE KEYHOLE LIMPET HEMOCYANIN CONJUGATE VACCINE; UNCLASSIFIED DRUG;

ACTIVE IMMUNIZATION; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY BLOOD LEVEL; ANTIBODY PRODUCTION; ANTIBODY TITER; ARTICLE; CONTROLLED STUDY; DRUG EFFECT; FEMALE; LOCOMOTION; METHAMPHETAMINE DEPENDENCE; MOUSE; NONHUMAN; PLACE PREFERENCE; PRIORITY JOURNAL;

AMPHETAMINE-RELATED DISORDERS; ANIMALS; ANTIBODIES; BEHAVIOR, ANIMAL; CARRIER PROTEINS; CENTRAL NERVOUS SYSTEM STIMULANTS; CONDITIONING, OPERANT; DATA INTERPRETATION, STATISTICAL; DOSE-RESPONSE RELATIONSHIP, DRUG; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HEMOCYANIN; IMMUNIZATION; METHAMPHETAMINE; MICE; MICE, INBRED BALB C; MOTOR ACTIVITY; REWARD; VACCINES;

MUS;

EID: 84875244821     PISSN: 03768716     EISSN: 18790046     Source Type: Journal    
DOI: 10.1016/j.drugalcdep.2012.09.007     Document Type: Article

References (41)

1. Aguilar M.A., Rodriguez-Arias M., Minarro J. Neurobiological mechanisms of the reinstatement of drug-conditioned place preference. Brain Res. Rev. 2009, 59:253-277.
2. Antoniou K., Kafetaopoulos E., Papadopoulou-Daifoti Z., Hyphantis T., Marselos M. d-Amphetamine, cocaine and caffeine: a comparative study of acute effects on locomotor activity and behavioural patterns in rats. Neurosci. Biobehav. Rev. 1998, 23:189-196.
3. Bardo M.T., Bevins R.A. Conditioned place preference: what does it add to our preclinical understanding of drug reward?. Psychopharmacology 2000, 153:31-43.
4. Brien J.F., Kitney J.C., Peachey J.E., Rogers B.J. Methamphetamine-induced behavioural effects and brain concentrations of methamphetamine and its metabolite amphetamine in mice. Res. Commun. Chem. Pathol. Pharmacol. 1978, 22:313-318.
5. Byrnes-Blake K.A., Carroll F.I., Abraham P., Owens S.M. Generation of anti-(+)methamphetamine antibodies is not impeded by (+)methamphetamine administration during active immunization of rats. Int. Immunopharmacol. 2001, 1:329-338.
6. Byrnes-Blake K.A., Laurenzana E.M., Landes R.D., Gentry W.B., Owens S.M. Monoclonal IgG affinity and treatment time alters antagonism of (+)-methamphetamine effects in rats. Eur. J. Pharmacol. 2005, 521:86-94.
7. Carr G.D., Fibiger H.C., Phillips A.G. Conditioned place preference as a measure of drug reward. The Neuropharmacological Basis of Reward 1989, 264-319. Oxford University Press, New York. J. Liebman, S. Cooper (Eds.).
8. Dagan R., Poolman J., Siegrist C.-A. Glycoconjugate vaccines and immune interference: a review. Vaccine 2010, 28:5513-5523.
9. Darke S., Kaye S., McKetin R., Duflou J. Major physical and psychological harms of methamphetamine use. Drug Alcohol Rev. 2008, 27:253-262.
10. Duryee M.J., Bevins R.A., Reichel C.M., Murray J.E., Dong Y., Thiele G.M., Sanderson S.D. Immune responses to methamphetamine by active immunization with peptide-based, molecular adjuvant-containing vaccines. Vaccine 2009, 27:2981-2988.
11. Ellinwood E.H., Balster R.L. Rating the behavioral effects of amphetamine. Eur. J. Pharmacol. 1974, 28:35-41.
12. Ettinger R.H., Ettinger W.F., Harless W.E. Active immunization with cocaine-protein conjugate attenuates cocaine effects. Pharmacol. Biochem. Behav. 1997, 58:215-220.
13. Fowler J.S., Kroll C., Ferrieri R., Alexoff D., Logan J., Dewey S.L., Schiffer W., Schlyer D., Carter P., King P., Shea C., Xu Y., Muench L., Benveniste H., Vaska P., Volkow N.D. PET studies of d-Methamphetamine pharmacokinetics in primates: comparison with l-methamphetamine and (-)-cocaine. J. Nucl. Med. 2007, 48:1724-1732.
14. Gentry W.B., Laurenzana E.M., WIlliams D.K., West J.R., Berg R.J., Terlea T., Owens S.M. Safety and efficiency of an anti-(+)-methamphetamine monoclonal antibody in the protection against cardiovascular and central nervous system effects of (+)-methamphetamine in rats. Int. Immunopharmacol. 2006, 6:968-977.
15. George F.R. Cocaine produces low dose locomotor depressant effects in mice. Psychopharmacology 1989, 99:147-150.
16. George F.R. Cocaine produces low dose locomotor depressant effects in NBR and F344 rats. Pharmacol. Biochem. Behav. 1990, 37:795-798.
17. Gonzales R., Mooney L., Rawson R.A. The methamphetamine problem in the United States. Ann. Rev. Public Health 2010, 31:385-398.
18. Hatsukami D.K., Jorenby D.E., Donzales G., Aigotti R.N., Glover E.D., Oncken C.A., Tashkin D.P., Reus V.I., Akhavain R.C., Fahim R.E., Kessler P.D., Niknian M., Kalnik M.W., Rennard S.I. Immunogenicity and smoking-cessation outcomes for a novel nicotine immunotherapeutic. Clin. Pharmacol. Ther. 2011, 89:392-399.
19. Hatsukami D.K., Rennard S., Jorenby D., Fiore M., Koopmeiners J., deVos A., Horwith G., Pentel P.R. Safety and immunogenicity of a nicotine conjugate vaccine in current smokers. Clin. Pharmacol. Ther. 2005, 78:456-467.
20. Itzhak Y., Ali S.F. Behavioral consequences of methamphetamine-induced neurotoxicity in mice: relevance to the psychopathology of methamphetamine addiction. Ann. N.Y. Acad. Sci. 2002, 965:127-135.
21. Itzhak Y., Martin J.L., Ali S.F. Methamphetamine-induced dopaminergic neurotoxicity in mice: long-lasting sensitization to the locomotor stimulation and desensitization to the rewarding effects of methamphetamine. Prog. Neuropsychopharmacol. Biol. Psychiatry 2002, 26:1177-1183.
22. Josefsberg J.O., Buckland B. Vaccine process technology. Biotechnol. Bioeng. 2012, 109:1443-1460.
23. Kitahama K., Valatx J.-L. Strain differences in amphetamine sensitivity in mice. Psychopharmacology 1979, 66:189-194.
24. Kuczenski R., Segal D.S. Concomitant characterization of behavioral and striatal neurotransmitter response to amphetamine using in vivo microdialysis. J. Neurosci. 1989, 9:2051-2065.
25. Martell B.A., Orson F.M., Poling J., Mitchell E., Rossen R.D., Gardner T., Kosten T.R. Cocaine vaccine for the treatment of cocaine dependence in methadone-maintained patients: a randomized, double-blind, placebo-controlled efficacy trial. Arch. Gen. Psychiatry 2009, 66:1116-1123.
26. Maurer P., Bachmann M.F. Vaccination against nicotine: an emerging therapy for tobacco dependence. Expert Opin. Investig. Drugs 2007, 16:1775-1783.
27. McKetin R., Kozel N., Doublas J., Ali R., Vicknasingam B., Lund J., Li J.H. The rise of methamphetamine in Southeast and East Asia. Drug Alcohol Rev. 2008, 27:220-228.
28. McMillan D.E., Hardwick W.C., Li M., Gunnell M.G., Carroll F.I., Abraham P., Owens S.M. Effects of murine-derived anti-methamphetamine monoclonal antibodies on (+)-methamphetamine self-administration in the rat. J. Pharmacol. Exp. Ther. 2004, 309:1248-1255.
29. McMillan D.E., Hardwick W.C., Li M., Owens S.M. Pharmacokinetic antagonism of (+) -methamphetamine discrimination by a low-affinity monoclonal anti-methamphetamine antibody. Behav. Pharmacol. 2002, 13:465-473.
30. Montomoli E. Current adjuvants and new perspectives in vaccine formulation. Exp. Rev. 2010, 10:1053-1061.
31. Moreno A.Y., Mayorov A.V., Janda K.D. Impact of distinct chemical structures for the development of a methamphetamine vaccine. J. Am. Chem. Soc. 2011, 4:6587-6595.
32. Peterson E.C., Gunnell M., Che Y., Goforth R.L., Carroll F.I., Henry R., Liu H., Owens S.M. Using hapten design to discover therapeutic monoclonal antibodies for treating methamphetamine abuse. J. Pharmacol. Exp. Ther. 2007, 322:30-39.
33. Schechter M.D., Calcagnetti D.J. Trends in place preference conditioning with a cross-indexed bibliography, 1957-1991. Pharmacol. Biochem. Behav. 1993, 17:21-41.
34. Shabani S., McKinnon C., Cunningham C., Phillips T. Profound reduction in sensitivity to the aversive effects of methamphetamine in mice bred for high methamphetamine intake. Neuropharmacology 2011, 62:1134-1141.
35. Shabani S., McKinnon C.S., Reed C., Cunningham C.L., Phillips T.J. Sensitivity to rewarding or aversive effects of methamphetamine determines methamphetamine intake. Genes Brain Behav. 2011, 10:625-636.
36. Singh R.A.K., Kosten T.A., Kinsey B.M., Shen X., Lopez A.Y., Kosten T.R., Orson F.M. Dose-dependent changes in the locomotor responses to methamphetamine in BALB/c mice: low doses induce hypolocomotion. Pharmacol. Biochem. Behav. 2012, 103:230-236.
37. Sulzer D., Sonders M.S., Poulsen N.W., Galli A. Mechanisms of neurotransmitter release by amphetamines: a review. Prog. Neurobiol. 2005, 75:406-433.
38. Thomsen M., Caine S.B. Psychomotor stimulant effects of cocaine in rats and 15 mouse strains. Exp. Clin. Psychopharmacol. 2011, 19:321-341.
39. Tzschentke T.M. Measuring reward with the conditioned place preference paradigm: a comprehensive review of drug effects, recent progress and new issues. Prog. Neurobiol. 1998, 56:613-672.
40. Volkow N.D., Fowler J.S., Wang G.J., Shumay E., Telang F., Thanos P.K., Alexoff D. Distribution and pharmacokinetics of methamphetamine in the human body: clinical implications. PloS One 2010, 7:5.
41. Wheeler J.M., Reed C., Burkhart-Kasch S., Li N., Cunningham C.L., Janowsky A., Franken F.H., Wiren K.M., Hashimoto J.G., Scibelli A.C., Phillips T.J. Genetically correlated effects of selective breeding for high and low methamphetamine consumption. Genes Brain Behav. 2009, 8:758-771.